Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Neoplasms 9Carcinoma, Non-Small-Cell Lung 7Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms 3Solid Tumors 2Melanoma 2Carcinoma 2Adult Solid Neoplasm 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Neoplasm 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Renal Insufficiency 1Prostatic Neoplasms 1Paraproteinemias 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteolysis 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma, Malignant 1Malignant Solid Tumour 1Liver Neoplasms 1Hypercalcemia 1Hematologic Neoplasms 1Fractures, Spontaneous 1

Interventions

Dexamethasone 7Bortezomib 4Lenalidomide 3pomalidomide 2glucarpidase 2Kidney Transplantation 2Bendamustine Hydrochloride 2Azacitidine 2vinflunine 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1osimertinib 1mirabegron 1gamma-Glutamyl Hydrolase 1copanlisib 1carfilzomib 1Zoledronic Acid 1Urinalysis 1Topotecan 1Thalidomide 1Tablets 1Stents 1Sitagliptin Phosphate 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Renal Insufficiency × ARQ 197 × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡